4 result(s) have been found!
| Accession | Name | Sequence | Source/Organism | Mechanism | Assay Type | Cell Line | Cancer Type | Activity |
|---|---|---|---|---|---|---|---|---|
| dbacp03352 | Hymenochirin-1B | KLSPETKDNLKKVLKGAIKGAIVAKMV | Zaire dwarf clawed frog | Membrane disruption and cell lysis | Cytotoxicity assay, Cell TiterGlo Luminescent Cell viability assay | A549 | Lung cancer | LC50 : 2.5 ± 0.2 μM |
| dbacp03353 | Hymenochirin-1B | KLSPETKDNLKKVLKGAIKGAIVAKMV | Zaire dwarf clawed frog | Membrane disruption and cell lysis | Cytotoxicity assay, Cell TiterGlo Luminescent Cell viability assay | MDA-MB-231 | Breast cancer | LC50 : 9.0 ± 0.3 μM |
| dbacp03354 | Hymenochirin-1B | KLSPETKDNLKKVLKGAIKGAIVAKMV | Zaire dwarf clawed frog | Membrane disruption and cell lysis | Cytotoxicity assay, Cell TiterGlo Luminescent Cell viability assay | HT-29 | Colon cancer | LC50 : 9.7 ± 0.2 μM |
| dbacp03355 | Hymenochirin-1B | KLSPETKDNLKKVLKGAIKGAIVAKMV | Zaire dwarf clawed frog | Membrane disruption and cell lysis | Cytotoxicity assay, Cell TiterGlo Luminescent Cell viability assay | HepG2 | Liver cancer | LC50 : 22.5 ± 1.4 μM |